Alessandro Leonetti

3.3k total citations · 1 hit paper
54 papers, 2.0k citations indexed

About

Alessandro Leonetti is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Alessandro Leonetti has authored 54 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 32 papers in Pulmonary and Respiratory Medicine and 15 papers in Molecular Biology. Recurrent topics in Alessandro Leonetti's work include Lung Cancer Treatments and Mutations (27 papers), Lung Cancer Research Studies (16 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Alessandro Leonetti is often cited by papers focused on Lung Cancer Treatments and Mutations (27 papers), Lung Cancer Research Studies (16 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Alessandro Leonetti collaborates with scholars based in Italy, Netherlands and United States. Alessandro Leonetti's co-authors include Elisa Giovannetti, Roberta Minari, Paola Perego, Marcello Tiseo, Sugandhi Sharma, Marcello Tiseo, Christian Rolfo, Sebastiano Buti, Yehuda G. Assaraf and Giulia Mazzaschi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and British Journal of Cancer.

In The Last Decade

Alessandro Leonetti

51 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

2019 893 citations Alessandro Leonetti, Roberta Minari et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alessandro Leonetti Italy	18	1.2k	1.1k	848	424	157	54	2.0k
Francesco Facchinetti Italy	25	1.2k 1.0×	1.1k 1.0×	827 1.0×	386 0.9×	176 1.1×	79	2.1k
Eiki Ichihara Japan	29	1.5k 1.2×	1.6k 1.5×	945 1.1×	395 0.9×	195 1.2×	153	2.4k
Roberta Minari Italy	25	1.7k 1.4×	1.5k 1.3×	1.1k 1.4×	585 1.4×	208 1.3×	66	2.5k
Soji Kakiuchi Japan	21	910 0.8×	850 0.8×	998 1.2×	313 0.7×	116 0.7×	41	1.9k
Shang‐Gin Wu Taiwan	29	1.9k 1.6×	1.5k 1.3×	955 1.1×	683 1.6×	160 1.0×	64	2.6k
Kenji Tomizawa Japan	26	1.5k 1.2×	1.3k 1.2×	874 1.0×	393 0.9×	142 0.9×	72	2.4k
Kazuhiko Shien Japan	23	863 0.7×	885 0.8×	955 1.1×	563 1.3×	120 0.8×	121	2.0k
Carlota Costa Spain	19	747 0.6×	768 0.7×	785 0.9×	399 0.9×	175 1.1×	41	1.6k
Chiara Lazzari Italy	24	738 0.6×	883 0.8×	580 0.7×	313 0.7×	103 0.7×	67	1.5k
Yuji Minegishi Japan	24	1.2k 1.0×	1.1k 1.0×	987 1.2×	510 1.2×	93 0.6×	72	2.2k

Countries citing papers authored by Alessandro Leonetti

Since Specialization

Citations

This map shows the geographic impact of Alessandro Leonetti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alessandro Leonetti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alessandro Leonetti more than expected).

Fields of papers citing papers by Alessandro Leonetti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alessandro Leonetti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alessandro Leonetti. The network helps show where Alessandro Leonetti may publish in the future.

Co-authorship network of co-authors of Alessandro Leonetti

This figure shows the co-authorship network connecting the top 25 collaborators of Alessandro Leonetti. A scholar is included among the top collaborators of Alessandro Leonetti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alessandro Leonetti. Alessandro Leonetti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Leonetti, Alessandro, Roberta Minari, Francesco Bonatti, et al.. (2024). Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC. Clinical Lung Cancer. 25(8). e436–e445.e9. 2 indexed citations

Volta, Francesco, Silvia La Monica, Alessandro Leonetti, et al.. (2023). Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators. Targeted Oncology. 18(6). 953–964. 8 indexed citations

Lococo, Filippo, Alessandra Cancellieri, Marco Chiappetta, et al.. (2023). Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results. Clinical Lung Cancer. 24(5). 467–473. 4 indexed citations

Ventura, Luigi, Letizia Gnetti, Gianluca Milanese, et al.. (2023). Relationship Between the Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) and Lung Adenocarcinoma Patterns: New Possible Insights. Archivos de Bronconeumología. 59(7). 418–426.

Leonetti, Alessandro, Giulia Mazzaschi, Fabiana Perrone, et al.. (2023). Thirty-day mortality in hospitalised patients with lung cancer: incidence and predictors. BMJ Supportive & Palliative Care. 14(e2). e2003–e2010. 1 indexed citations

Buti, Sebastiano, et al.. (2022). Takotsubo Syndrome in a Patient with Metastatic Renal Cell Carcinoma Treated with Pembrolizumab Plus Axitinib. Immunotherapy. 14(16). 1297–1305. 5 indexed citations

Leonetti, Alessandro, Francesco Bonatti, Fabiana Perrone, et al.. (2022). Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review. Translational Lung Cancer Research. 11(12). 2588–2600. 13 indexed citations

Leonetti, Alessandro, et al.. (2022). Small cell lung cancer: Novel treatments beyond immunotherapy. Seminars in Cancer Biology. 86(Pt 2). 376–385. 55 indexed citations

Minari, Roberta, Francesco Bonatti, Giulia Mazzaschi, et al.. (2021). PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors. Tumori Journal. 108(1). 47–55. 9 indexed citations

10.

Mazzaschi, Giulia, Alessandro Leonetti, Roberta Minari, et al.. (2021). Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy. Current Treatment Options in Oncology. 22(11). 96–96. 10 indexed citations

11.

Sundaresan, Janani, Alessandro Leonetti, Marcello Tiseo, et al.. (2021). Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?. Critical Reviews in Oncology/Hematology. 166. 103454–103454. 20 indexed citations

12.

Bersanelli, Melissa, Fabiana Perrone, Roberta Camisa, et al.. (2020). Clinical Impact of COVID-19 in a Single-Center Cohort of a Prospective Study in Cancer Patients Receiving Immunotherapy. Immunotherapy. 12(15). 1139–1148. 7 indexed citations

13.

Mazzaschi, Giulia, Roberta Minari, Alessandra Zecca, et al.. (2020). Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients. Lung Cancer. 148. 1–11. 82 indexed citations

14.

Steen, Nele Van Der, Alessandro Leonetti, Kaylee M. Keller, et al.. (2019). Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line. Biochemical Pharmacology. 166. 128–138. 13 indexed citations

15.

Steen, Nele Van Der, Elisa Giovannetti, Daniela Carbone, et al.. (2018). Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer. Cancer Drug Resistance. 22 indexed citations

16.

Minari, Roberta, Paola Bordi, Silvia La Monica, et al.. (2018). Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC. Journal of Thoracic Oncology. 13(6). e89–e91. 33 indexed citations

17.

Leonetti, Alessandro, Francesco Facchinetti, Giulio Rossi, et al.. (2018). BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall. Cancer Treatment Reviews. 66. 82–94. 121 indexed citations

18.

Facchinetti, Francesco, Paola Bordi, Alessandro Leonetti, Sebastiano Buti, & Marcello Tiseo. (2018). Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. Drug Design Development and Therapy. Volume 12. 2857–2873. 7 indexed citations

19.

Gelsomino, Francesco, Alessandro Leonetti, Karim Rihawi, et al.. (2017). Immune checkpoint inhibition in small cell lung cancer: a key to reach an unmet need?. Translational Cancer Research. 6. 2 indexed citations

20.

Leonetti, Alessandro, Melissa Bersanelli, B. Castagneto, et al.. (2016). Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review. Clinical Genitourinary Cancer. 14(4). 277–283. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact